Quantum BioPharma (QNTM) Fundamental Analysis: Revenue, Earnings & Valuation

3.75 / 10

Netural

Fundamental analysis rates the stock at about 3.8/10, indicating a weak profile. Strengths include strong accounts receivable turnover, interest coverage and inventory turnover, while fixed‑asset turnover and income‑tax ratio drag performance.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight45.06%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight2.39%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-2.56%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-2.53%

1M Return-0.65%

PB-ROE

Value2.29

Score2/3

Weight50.52%

1M Return8.98%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-5.76%

1M Return-1.54%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-4.75%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-2.86%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-2.81%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight23.30%

1M Return4.88%

Is QNTM undervalued or overvalued?

QNTM scores 3.75/10 on fundamentals and holds a Fair valuation at present. Backed by its -257.97% ROE, 0.00% net margin, -0.64 P/E ratio, 2.42 P/B ratio, and 30.90% earnings growth, these metrics solidify its Netural investment rating.